SynthesisPloS one2017
Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- [Conservative and pharmacological treatment of benign prostatic hyperplasia : The German S2e-guideline 2023-part2].Urologie (Heidelberg, Germany) · 2023Guideline
- Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction.The Cochrane database of systematic reviews · 2021Pooled it
- Prescription Trends in the Management of Lower Urinary Tract Symptoms in Men: An Online Survey of Indian Urologists.Cureus · 2026Article
- Association between the subsequent benign prostate hyperplasia-related surgery risk and patients treated with Chinese herbal medicine: a population-based Taiwanese cohort study.BMC complementary medicine and therapies · 2026Article
- [Pharmacotherapy of benign prostatic syndrome : Medications, innovations and future prospects].Urologie (Heidelberg, Germany) · 2026Review
- Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Prescription Trends of Initial Pharmacotherapy for Benign Prostatic Hyperplasia Among Treatment-Naïve Patients in South Korea: A Retrospective Analysis.Lower urinary tract symptoms · 2025Article
- Management and Treatment of Benign Prostatic Hyperplasia Symptoms: Current Insights.Research and reports in urology · 2025Review
- Efficacy of Combined Therapy With Silodosin and Solifenacin in Females With Overactive Bladder.International neurourology journal · 2024Article
- Treating LUTS in Men with Benign Prostatic Obstruction: A Review Article.Drugs & aging · 2023Review
- Review
- [Benign prostatic obstruction-associated symptoms of the lower urinary tract : Treatment with anticholinergics in combination with alpha-blockers].Der Urologe. Ausg. A · 2021Article
- Current Treatment for Benign Prostatic Hyperplasia.Deutsches Arzteblatt international · 2020Review
- Drugs for benign prostatic hypertrophy.Australian prescriber · 2018Review
- Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats.International neurourology journal · 2018Article
- Re: Insufficient conclusions regarding the association between overactive bladder symptoms and degree of dementia.International braz j urol : official journal of the Brazilian Society of UrologyArticle
- The Relationship Between Lower Urinary Tract Symptoms and Severity of Alzheimer's Disease.American journal of Alzheimer's disease and other dementiasArticle
- The Urological Society of India guidelines on management of benign prostatic hyperplasia/benign prostatic obstruction (Executive summary).Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is still controversy as to whether initial combination treatment is superior to serial addition of anticholinergics after maintenance or induction of alpha blockers in benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS).
objectiveThe objective of this study was to determine the benefits and safety of initial combination treatment of an alpha blocker with anticholinergic medication in BPH/LUTS through a systematic review and meta-analysis.
methodsWe conducted a meta-analysis of improvement in LUTS using International Prostate Symptom Score (IPSS), maximal urinary flow rate (Qmax), post-voided residual volume (PVR), and quality of life (QoL).
resultsIn total, 16 studies were included in our analysis, with a total sample size of 3,548 subjects (2,195 experimental subjects and 1,353 controls). The mean change in total IPSS improvement from baseline in the combination group versus the alpha blocker monotherapy group was -0.03 (95% CI: -0.14-0.08). The pooled overall SMD change of storage IPSS improvement from baseline was -0.28 (95% CI: -0.40 - -0.17). The pooled overall SMD changes of QoL, Qmax, and PVR were -0.29 (95% CI: -0.50 - -0.07), 0.00 (95% CI: -0.08-0.08), and 0.56 (95% CI: 0.23-0.89), respectively. There was no significant difference in the number of acute urinary retention (AUR) events or PVR.
conclusionsInitial combination treatment of an alpha blocker with anticholinergic medication is efficacious for in BPH/ LUTS with improved measures such as storage symptoms and QoL without causing significant deterioration of voiding function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.